Experts allay Covaxin concerns, say 50% effectiveness against Delta-driven Covid surge not bad
The Hindu
The results of the first real-world assessment of Covaxin published in The Lancet Infectious Diseases journal
The decline in the effectiveness of Covaxin, India’s indigenous COVID-19 vaccine, from 77.8% to 50% during a Delta-driven case surge in April and May this year is neither bad nor surprising, say scientists.
The differing figures led to some concern, particularly among those who had received Covaxin, but several scientists allayed the misgivings, pointing to the potency of the Delta strain, the intensity of the second Covid wave in India and the level of exposure among healthcare workers.
The results of the published in The Lancet Infectious Diseases journal on Wednesday showed that two doses of the vaccine, also known as BBV152, are 50% effective against the symptomatic disease.